Biotech Values

[randychub]

As I said, "They have a nmp22 for bladder on the market that works differently and is not as accurate as these prelimary testing results". NMP22 test is done with a urine sample.

All nmp66, nmp35, and nmp48 will use blood. I doubt that the in clinic testing will ever be as accurate as mass spec testing but it may become accurate enough to be used. Again the work has to be done by their partners which I think they have choosen very well. Mass spec is what will work if anything works.


And yes the nmp22 does have a way to go but nothing currently on the market works better. I would not invest in this company based on nmp22. In fact if interested you could probably wait until you see mass spec results.


"Dr. Peter Oehr of the University of Bonn reported the results of using the NMP22 BladderChek Test for initial diagnosis of patients who presented with hematuria (blood in the urine). The study included 212 hematuria patients at 16 urologists' offices, of whom 113 also had cytology performed. The NMP22 BladderChek Test detected 82% of the bladder cancers compared to only 57% found by cytology, thereby demonstrating that the NMP22 BladderChek Test is more accurate than cytology at identifying patients with bladder tumors. Both tests ruled out 97% of the patients without cancer. The study also confirmed that the presence of blood in the urine did not interfere with the NMP22
A second investigation presented at the EAU meeting demonstrated that the NMP22 BladderChek Test is clinically useful for monitoring patients who have undergone a common treatment for bladder cancer called BCG. This study, conducted at the University of Barcelona in Spain, monitored 23 patients during their first evaluation following treatment with BCG. The NMP22 BladderChek Test showed no interference from the immunotherapy, and correctly identified 93% of the patients who were free of cancer, demonstrating that it is a very effective tool for managing patients following treatment with BCG.

In the third study, Dr. Gerson Ludecke at the University of Giessen in Germany reported that NMP22 protein would be suitable as a screening marker for bladder cancer in defined risk populations based on the product's excellent performance identifying patients without bladder cancer. Dr. Ludecke reviewed NMP22 values from 517 patients with a variety of urological cancers and other urinary tract disorders and 39 volunteers as controls. NMP22 was accurately negative in 92% of both the control group and patients with urological malignancies other than of the bladder, and detected 75% of the bladder tumors.